What is Spyre Therapeutics Inc. (SYRE) stock price today?

Spyre Therapeutics Inc. (SYRE) currently trades at $71.89 per share. The stock has a market capitalization of $6.20B and a P/E ratio of —x.

Is SYRE stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Spyre Therapeutics Inc. has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 1.09.

Is Spyre Therapeutics Inc. financially healthy?

Spyre Therapeutics Inc.'s Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 1.09 places it in the distress.

SYRE

Spyre Therapeutics Inc.

NASDAQ: SYRE · HEALTHCARE · BIOTECHNOLOGY

$71.89

+4.75% today

Updated 2026-04-29

Market cap

$6.20B

P/E ratio

—

P/S ratio

650.22x

EPS (TTM)

$-1.98

Dividend yield

—

52W range

$12 – $75

Volume

1.1M

Market cap

$6.20B

P/E ratio

—

P/S ratio

650.22x

EPS (TTM)

$-1.98

Dividend yield

—

52W range

$12 – $75

Volume

1.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

5.8

Quality

C+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

1.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$90.13

+25.37%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy16 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Altman Z 1.09 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-44.58M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$2.33M	$886000.00	$886000.00	$0.00	$90.49M
Net income	$-83.81M	$-338.79M	$-208.02M	$-155.20M	$-62.53M
EPS	—	—	—	—	$-1.98
Free cash flow	$-80.18M	$-99.91M	$-157.41M	$-169.25M	$-44.58M
Profit margin	-3,598.75%	-38,238.15%	-23,478.33%	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SYRE	$6.20B	23	3.7	3.0	5.0	5.8	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Spyre Therapeutics Inc. trades at $71.89. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.09, it sits in the distress.

Frequently asked questions

What is Spyre Therapeutics Inc.'s stock price?

Spyre Therapeutics Inc. (SYRE) trades at $71.89.

Is Spyre Therapeutics Inc. overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Spyre Therapeutics Inc. (SYRE)?

The analyst target price is $90.13, representing +25.4% upside from the current price of $71.89.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

1.09 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio650.22x

ROE-25.20%

Beta2.94

50D MA$50.79

200D MA$30.67

Shares out0.09B

Float0.07B

Short ratio—

Avg volume1.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

SYRE vs LLY →SYRE vs JNJ →SYRE vs ABBV →Stock screener →